中国生物制药完成收购赫吉亚100%股权

Core Viewpoint - China Biopharmaceutical (01177) announced the acquisition of 100% equity in Hejia, with all conditions precedent for the transaction being fulfilled and the completion date set for March 30, 2026. Following the completion, Hejia will become a wholly-owned subsidiary, and its financial performance will be consolidated into the group's financial statements [1]. Group 1 - The acquisition involves the issuance of consideration shares under a general mandate [1]. - The board expressed satisfaction with the fulfillment of all conditions precedent for the transaction [1]. - Hejia's financial results will be integrated into China Biopharmaceutical's financial reports post-acquisition [1].